Efficacy and safety of topical spironolactone 5% gel versus placebo in the treatment of acne vulgaris

被引:5
|
作者
Attwa, Enayat M. [1 ]
Ibrahim, Al Shimaa M. [1 ]
Abd El-Halim, Marwa F. [2 ]
Mahmoud, Hanan M. [3 ]
机构
[1] Zagazig Univ, Fac Med, Dept Dermatol Venereol & Androl, Zagazig, Egypt
[2] Zagazig Gen Hosp, Dept Dermatol, Zagazig, Egypt
[3] Zagazig Univ, Dept Pharmaceut, Fac Pharm, Zagazig, Egypt
来源
关键词
acne vulgaris; placebo; spironolactone gel;
D O I
10.4103/ejdv.ejdv_36_18
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Acne is an inflammatory disorder of the pilosebaceous unit that imposes negative effects on the psychological state of patients. Indeed, even mild acne can adversely affect the patients' quality of life. Therefore, successful management is needed. Spironolactone is one of the effective systemic treatments for acne, but its adverse effects limit its use. Objectives To assess the effectiveness and safety of 5% spironolactone gel in the treatment of acne. Patients and methods This study was a split-face study in which 22 adult patients with mild and moderate acne vulgaris were instructed to apply topical 5% spironolactone gel to their right hemifaces and topical placebo gel to their left hemifaces twice daily for 8 weeks. Results This study reported a statistically significant reduction in the total lesion count and acne severity index from the baseline. The improvement was significantly higher in the spironolactone side than the placebo side. Spironolactone mainly improves comedones and inflammatory papules. Minimal tolerable adverse effects were recorded in the form of stinging and mild erythema. Conclusion The data provided by this study support the use of topical spironolactone in the treatment of mild to moderate acne vulgaris.
引用
收藏
页码:89 / 94
页数:6
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF CD-271 ALCOHOLIC GELS IN THE TOPICAL TREATMENT OF ACNE-VULGARIS
    VERSCHOORE, M
    LANGNER, A
    WOLSKA, H
    JABLONSKA, S
    CZERNIELEWSKI, J
    SCHAEFER, H
    BRITISH JOURNAL OF DERMATOLOGY, 1991, 124 (04) : 368 - 371
  • [32] Dapsone 5% GelA Review of its Efficacy and Safety in the Treatment of Acne Vulgaris
    Mira Stotland
    Alan R. Shalita
    Robert F. Kissling
    American Journal of Clinical Dermatology, 2009, 10 : 221 - 227
  • [33] Topical metformin 30% gel in the treatment of acne vulgaris in women, a split face, placebo-controlled study
    EL-Komy, Mohamed H. M.
    Abdo, Nesma Moustafa Kamel
    Shamma, Rehab Nabil
    Bedair, Nermeen Ibrahim
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (10) : 1663 - 1673
  • [34] Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
    Epstein, Erica L.
    Gold, Linda Stein
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2013, 6 : 123 - 125
  • [35] ACNE-VULGARIS - TREATMENT WITH TOPICAL BENZOYL PEROXIDE ACETONE GEL
    MONTES, LF
    CUTIS, 1977, 19 (05): : 681 - 685
  • [36] Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris
    Brumfiel, Caitlin M.
    Patel, Meera H.
    Bell, Katheryn A.
    Cardis, Michael A.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 755 - 763
  • [37] EFFICACY AND TOLERANCE OF A MICONAZOLE-BENZOYL PEROXIDE CREAM COMBINATION VERSUS A BENZOYL PEROXIDE GEL IN THE TOPICAL TREATMENT OF ACNE-VULGARIS
    FLUCKIGER, R
    FURRER, HJ
    RUFLI, T
    DERMATOLOGICA, 1988, 177 (02): : 109 - 114
  • [38] Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris
    Diane M. Thiboutot
    Jonathan Willmer
    Harry Sharata
    Rebat Halder
    Steven Garrett
    Clinical Pharmacokinetics, 2007, 46 : 697 - 712
  • [39] Comparison of the efficacy and safety of topical clindamycin and 5% benzoyl peroxide with nadifloxacin cream and 5% benzoyl peroxide gel in the treatment of acne vulgaris and assessment of the effects of these treatments on quality of life
    Kirkagac, Aslihan
    Saracoglu, Zeynep Nurhan
    Aksu, Ayse Esra Koku
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2015, 49 (01): : 54 - 59
  • [40] Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris
    Thiboutot, Diane M.
    Willmer, Jonathan
    Sharata, Harry
    Halder, Rebat
    Garrett, Steven
    CLINICAL PHARMACOKINETICS, 2007, 46 (08) : 697 - 712